SOURCE: Industrial Info Resources

Industrial Info Resources

June 11, 2014 06:15 ET

Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwired - Jun 11, 2014) - Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It has become obvious that the Pharmaceutical-Biotech Industry considers mergers and acquisitions (M&A) a key factor to growth, and there appears to be no end in sight to this feeding frenzy. Many pundits have weighed in countless times that the days of big ticket M&A activity were winding down. On the contrary, a spate of recent deals and plans are in active play across the entire spectrum of the industry.

Other companies featured: Pfizer Incorporated (NYSE:PFE), AstraZeneca plc (NYSE:AZN), Merck & Company (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), Valeant Pharmaceuticals International Incorporated (NYSE:VRX), Allergan Incorporated (NYSE:AGN)

For details, view the entire article by subscribing to Industrial Info's Premium Industry News, or browse other breaking industrial news stories at

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, three offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the "Contact Us" page.

Contact Information

  • Contact:
    Joe Govreau